Company intelligence / Profile preview

Organicell Regenerative Medicine

Miami, Florida, United Statesaccessnewswire.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Organicell's lead product Zofin™ has received FDA approval for 18 eINDs and four Phase I/II randomized, placebo-controlled trials for COVID-19, COPD, Osteoarthritis, and COVID Long Haulers. An Expanded Access trial for Mild to Moderate COVID-19 was completed and published in December 2021. No severe adverse events have been reported with Zofin™. The company is planning to launch Phase II trials for Zofin™ in 2025.

Therapeutic areas: PulmonologyEndocrinologyRheumatologyNeurologyInfectious Diseases
Modalities: ExosomesExtracellular vesiclesMicroRNAsBiologic therapeutics
Industry: Biotech

Drug pipeline

1 asset

Zofin

Phase 1/2

Indications: COVID-19, Knee osteoarthritis

Partnerships

Regenerative Care Network

Beyond the preview

Go deeper on Organicell Regenerative Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Organicell Regenerative Medicine.

Explore the full profile